The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking

Clinical Lipidology

Volumn 7, Issue 1, 2012, Pages 79-91

  Cotman, Susan L ^a   Staropoli, John F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

autophagy; Batten disease; CLN3; endosome; Golgi; juvenile neuronal ceroid lipofuscinosis; lysosome; palmitoylation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN CLN3; UNCLASSIFIED DRUG;

ANTEROGRADE PROTEIN TRAFFICKING; BIOLOGICAL MODEL; CLN3 GENE; DISEASE ASSOCIATION; ENDOSOME; GENE; GENE DELETION; GOLGI COMPLEX; HUMAN; LYSOSOME; MISSENSE MUTATION; NERVE DEGENERATION; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONSET AGE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RETROGRADE PROTEIN TRAFFICKING; REVIEW;

EID: 84856835788     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.70     Document Type: Review

References (90)

1. Kohlschutter A, Schulz A. Towards understanding the neuronal ceroid lipofuscinoses. Brain Dev. 31(7), 499-502 (2009).
2. Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta 1793(4), 697-709 (2009).
3. Mole S, Williams R, Goebel H. The Neuronal Ceroid Lipofuscinoses (Batten Disease). (2nd Edition). Oxford University Press, UK (2011).
4. Mole S, Williams R, Goebel H. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 6(3), 107-126 (2005). (Pubitemid 41396987)
5. Chattopadhyay S, Ito M, Cooper J et al. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11(12), 1421-1431 (2002).
6. Castaneda J, Pearce D. Identifcation of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol. Dis. 29(1), 92-102 (2008). (Pubitemid 350180486)
7. Ostergaard J, Rasmussen T, Molgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 76(14), 1245-1251 (2011).
8. Hofman I, van der Wal A, Dingemans K, Becker A. Cardiac pathology in neuronal ceroid lipofuscinoses-a clinicopathologic correlation in three patients. Eur. J. Paediatr. Neurol. 5(Suppl. A), 213-217 (2001). (Pubitemid 32677142)
9. Lebrun A, Moll-Khosrawi P, Pohl S et al. Analysis of potential biomarkers and modifer genes affecting the clinical course of CLN3 disease. Mol. Med. doi:10.2119/molmed.2010.00241 (2011) (Epub ahead of print).
10. Seehafer S, Pearce D. You say lipofuscin, we say ceroid: defning autofuorescent storage material. Neurobiol. Aging 27(4), 576-588 (2006). (Pubitemid 43290526)
11. Bruhn H. A short guided tour through functional and structural features of saposin-like proteins. Biochem. J. 389(Pt 2), 249-257 (2005). (Pubitemid 41021127)
12. Matsuda J, Yoneshige A, Suzuki K. The function of sphingolipids in the nervous system: lessons learnt from mouse models of specifc sphingolipid activator protein defciencies. J. Neurochem. 103(Suppl. 1), 32-38 (2007).
13. Palmer D, Fearnley I, Walker J et al. Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am. J. Med. Genet. 42(4), 561-567 (1992).
14. Palmer D, Bayliss S, Westlake V. Batten disease and the ATP synthase subunit c turnover pathway: raising antibodies to subunit c. Am. J. Med. Genet. 57(2), 260-265 (1995).
15. Kominami E. What are the requirements for lysosomal degradation of subunit c of mitochondrial ATPase? IUBMB Life 54(2), 89-90 (2002).
16. Ju W, Wronska A, Moroziewicz D et al. Genotype-phenotype analyses of classic neuronal ceroid lipofuscinosis (NCLs): genetic predictions from clinical and pathological fndings. Beijing Da Xue Xue Bao 38(1), 41-48 (2006).
17. Tyynela J, Baumann M, Henseler M, Sandhoff K, Haltia M. Sphingolipid activator proteins in the neuronal ceroid-lipofuscinoses: an immunological study. Acta Neuropathol. 89(5), 391-398 (1995).
18. Lyly A, Von Schantz C, Heine C et al. Novel interactions of CLN5 support molecular networking between neuronal ceroid lipofuscinosis proteins. BMC Cell. Biol. 10, 83 (2009).
19. Persaud-Sawin D-A, Mousallem T, Wang C, Zucker A, Kominami E, Boustany R-M. Neuronal ceroid lipofuscinosis: a common pathway? Pediatr. Res. 61(2), 146-152 (2007). (Pubitemid 46146870)
20. Vesa J, Chin M, Oelgeschlager K et al. Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. Mol. Biol. Cell. 13(7), 2410-2420 (2002). (Pubitemid 34831344)
21. Getty A, Pearce D. Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cell. Mol. Life Sci. 68(3), 453-474 (2011).
22. Kyttala A, Lahtinen U, Braulke T, Hofmann S. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim. Biophys. Acta 1762(10), 920-933 (2006). (Pubitemid 44740123)
23. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 82 (6), 949-957 (1995).
24. Altschul S, Madden T, Schaffer A et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17), 3389-3402 (1997). (Pubitemid 27359211)
25. Baldwin S, Beal P, Yao S, King A, Cass C, Young J. The equilibrative nucleoside transporter family, SLC29. Pfugers Arch. 447(5), 735-743 (2004). (Pubitemid 38241459)
26. Ackley M, Governo R, Cass C, Young J, Baldwin S, King A. Control of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1. J. Physiol. 548(Pt 2), 507-517 (2003). (Pubitemid 36527472)
27. Pao S, Paulsen I, Saier M Jr. Major facilitator superfamily Microbiol. Mol. Biol. Rev. 62(1), 1-34 (1998).
28. Nugent T, Mole S, Jones D. The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental data. FEBS Lett. 582(7), 1019-1024 (2008).
29. Storch S, Pohl S, Quitsch A, Falley K, Braulke T C-terminal prenylation of the CLN3 membrane glycoprotein is required for effcient endosomal sorting to lysosomes. Traffic 8(4), 431-444 (2007). (Pubitemid 46421624)
30. Siintola E, Topcu M, Aula N et al. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am. J. Hum. Genet. 81(1), 136-146 (2007). (Pubitemid 47001163)
31. Narayan S, Rakheja D, Tan L, Pastor J, Bennett M. CLN3P, the Batten's disease protein, is a novel palmitoyl-protein Delta-9 desaturase. Ann. Neurol. 60(5), 570-577 (2006). (Pubitemid 44871799)
32. Narayan S, Tan L, Bennett M. Intermediate levels of neuronal palmitoyl-protein D-9 desaturase in heterozygotes for murine Batten disease. Mol. Genet. Metab. 93(1), 89-91 (2008). (Pubitemid 350236008)
33. Hofmann S, Atashband A, Cho S, Das A, Gupta P, Lu Jy. Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2). Curr. Mol. Med. 2(5), 423-437 (2002). (Pubitemid 34760025)
34. Noskova L, Stranecky V, Hartmannova H et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am. J. Hum. Genet. 89(2), 241-252 (2011).
35. Munroe P, Mitchison H, O'Rawe A et al. Spectrum of mutations in the Batten disease gene, CLN3. Am. J. Hum. Genet. 61(2), 310-316 (1997). (Pubitemid 27382306)
36. Gachet Y, Codlin S, Hyams J, Mole S. btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis. J. Cell. Sci. 118(Pt 23), 5525-5536 (2005). (Pubitemid 43079293)
37. Muzaffar N, Pearce D. Analysis of NCL Proteins from an evolutionary standpoint. Curr. Genom. 9(2), 115-136 (2008). (Pubitemid 351888529)
38. Sarpong A, Schottmann G, Ruther K et al. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X). Clin. Genet. 76(1), 38-45 (2009).
39. Aberg L, Lauronen L, Hamalainen J, Mole S, Autti T. A 30-year follow-up of a neuronal ceroid lipofuscinosis patient with mutations in CLN3 and protracted disease course. Pediatr. Neurol. 40(2), 134-137 (2009).
40. Haskell R, Carr C, Pearce D, Bennett M, Davidson B. Batten disease: evaluation of CLN3 mutations on protein localization and function. Hum. Mol. Genet. 9(5), 735-744 (2000). (Pubitemid 30162757)
41. Golabek A, Kida E, Walus M, Kaczmarski W, Wujek P, Wisniewski K. CLN3 disease process: missense point mutations and protein depletion in vitro. Eur. J. Paediatr. Neurol. 5(Suppl. A), 81-88 (2001). (Pubitemid 32677117)
42. Michalewski M, Kaczmarski W, Golabek A, Kida E, Kaczmarski A, Wisniewski K. Evidence for phosphorylation of CLN3 protein associated with Batten disease. Biochem. Biophys. Res. Commun. 253(2), 458-462 (1998). (Pubitemid 29026724)
43. Ezaki J, Takeda-Ezaki M, Koike M et al. Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J. Neurochem. 87(5), 1296-1308 (2003). (Pubitemid 37485085)
44. Jarvela I, Sainio M, Rantamaki T et al. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum. Mol. Genet. 7(1), 85-90 (1998). (Pubitemid 28040741)
45. Kida E, Kaczmarski W, Golabek A, Kaczmarski A, Michalewski M, Wisniewski K. Analysis of intracellular distribution and traffcking of the CLN3 protein in fusion with the green fuorescent protein in vitro. Mol. Genet. Metab. 66(4), 265-271 (1999). (Pubitemid 29390185)
46. Kyttala A, Ihrke G, Vesa J, Schell M, Luzio J. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol. Biol. Cell 15, 1313-1323 (2004). (Pubitemid 38316237)
47. Storch S, Pohl S, Braulke T. A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the batten disease-related CLN3 protein are required for effcient lysosomal targeting. J. Biol. Chem. 279(51), 53625-53634 (2004). (Pubitemid 40051870)
48. Kyttala A, Yliannala K, Schu P, Jalanko A, Luzio J. AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. J. Biol. Chem. 280(11), 10277-10283 (2005). (Pubitemid 40395883)
49. Oswald M, Palmer D, Damak S. Splicing variants in sheep CLN3, the gene underlying juvenile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 67(2), 169-175 (1999). (Pubitemid 29393245)
50. -/- mice and in Batten disease. Brain 127(Pt 8), 1748-1754 (2004). (Pubitemid 39061552)
51. Ballif B, Hornor S, Jenkins E et al. Discovery of a previously unrecognized microdeletion syndrome of 16p11.2-p12.2. Nat. Genet. 39(9), 1071-1073 (2007). (Pubitemid 47340655)
52. Barge-Schaapveld D, Maas S, Polstra A, Knegt L, Hennekam R. The atypical 16p11.2 deletion: a not so atypical microdeletion syndrome? Am. J. Med. Genet. A 155A(5), 1066-1072 (2011).
53. Cotman S, Vrbanac V, Lebel L et al. Cln3Dex7/8 knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11(22), 2709-2721 (2002). (Pubitemid 35214898)
54. Fossale E, Wolf P, Espinola J et al. Membrane traffcking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis. BMC Neurosci. 5, 57 (2004).
55. Cao Y, Staropoli J, Biswas S et al. Distinct early molecular responses to mutations causing vLINCL and JNCL presage ATP synthase subunit c accumulation in cerebellar cells. PLoS One 6(2), E17118 (2011).
56. Chan C, Mitchison H, Pearce D. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models. Hum. Mol. Genet. 17(21), 3332-3339 (2008).
57. Kitzmuller C, Haines R, Codlin S, Cutler D, Mole S. A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 17(2), 303-312 (2008).
58. Pullarkat R, Morris G. Farnesylation of Batten disease CLN3 protein. Neuropediatrics 28(1), 42-44 (1997). (Pubitemid 27283157)
59. Persaud-Sawin D, Mcnamara J, Vandongen R, Boustany R. A galactosylceramide binding domain is involved in traffcking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr. Res. 56(3), 449-463 (2004). (Pubitemid 39128832)
60. Cao Y, Espinola J, Fossale E et al. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 281(29), 20483-20493 (2006). (Pubitemid 44065821)
61. Pearce D, Sherman F. A yeast model for the study of Batten disease. Proc. Natl Acad. Sci. USA 95(12), 6915-6918 (1998). (Pubitemid 28278081)
62. Holopainen J, Saarikoski J, Kinnunen P, Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur. J. Biochem. 268(22), 5851-5856 (2001). (Pubitemid 33079320)
63. Kim Y, Ramirez-Montealegre D, Pearce D. A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc. Natl Acad. Sci. USA 100(26), 15458-15462 (2003). (Pubitemid 38021011)
64. Luiro K, Yliannala K, Ahtiainen L et al. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Hum. Mol. Genet. 13(23), 3017-3027 (2004). (Pubitemid 39585234)
65. Codlin S, Haines R, Burden J, Mole S. Btn1 affects cytokinesis and cell-wall deposition by independent mechanisms, one of which is linked to dysregulation of vacuole pH. J. Cell. Sci. 121(Pt 17), 2860-2870 (2008).
66. Luiro K, Kopra O, Lehtovirta M, Jalanko A. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum. Mol. Genet. 10(19), 2123-2131 (2001). (Pubitemid 32998824)
67. Kovacs A, Weimer J, Pearce D. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol. Dis. 22(3), 575-585 (2006). (Pubitemid 43832129)
68. Herrmann P, Druckrey-Fiskaaen C, Kouznetsova E et al. Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis. J. Neurosci. Res. 86(8), 1857-1870 (2008). (Pubitemid 351859435)
69. Finn R, Kovacs A, Pearce D. Altered sensitivity of cerebellar granule cells to glutamate receptor overactivation in the Cln3(Deltaex7/8)-knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. Neurochem. Int. 58(6), 648-655 (2011).
70. + ATPase complex. Exp. Cell. Res. 314(15), 2895-2905 (2008).
71. -/- cells. Exp. Cell. Res. 317(1), 51-69 (2011).
72. Rakheja D, Narayan S, Pastor J, Bennett M. CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes). Biochem. Biophys. Res. Commun. 317(4), 988-991 (2004). (Pubitemid 38496407)
73. Chang J, Choi H, Kim H et al. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin. Hum. Mol. Genet. 16(3), 317-326 (2007). (Pubitemid 46323187)
74. Persaud-Sawin D-A, Vandongen A, Boustany R-M. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. Hum. Mol. Genet. 11(18), 2129-2142 (2002). (Pubitemid 34994001)
75. Phillips S, Benedict J, Weimer J, Pearce D. CLN3, the protein associated with Batten disease: structure, function and localization. J. Neurosci. Res. 79, 573-583 (2005). (Pubitemid 40476436)
76. De Matteis MA, Luini A. Exiting the Golgi complex. Nat. Rev. Mol. Cell. Biol. 9(4), 273-284 (2008). (Pubitemid 351430855)
77. Wolfe DM, Padilla-Lopez S, Vitiello SP, Pearce DA. pH-dependent localization of Btn1p in the yeast model for Batten disease. Dis. Model. Mech. 4(1), 120-125 (2011).
78. Kama R, Kanneganti V, Ungermann C, Gerst J. The yeast Batten disease ortholog, Btn1, controls endosome-Golgi retrograde transport via SNARE assembly. J. Cell Biol. 195(2), 203-215 (2011).
79. Padilla-Lopez S, Pearce D. Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity in order to regulate pH imbalance in the vacuole. J. Biol. Chem. 281(15), 10273-10280 (2006). (Pubitemid 43864565)
80. Codlin S, Mole SE. S. pombe btn1, the orthologue of the Batten disease gene CLN3, is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p. J. Cell. Sci. 122(Pt 8), 1163-1173 (2009).
81. Metcalf D, Calvi A, Seaman M, Mitchison H, Cutler D. Loss of the Batten disease gene CLN3 prevents exit from the TGN of the mannose 6-phosphate receptor. Traffic 9(11), 1905-1914 (2008).
82. Pearce D, Ferea T, Nosel S, Das B, Sherman F. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease. Nat. Genet. 22(1), 55-58 (1999). (Pubitemid 29214804)
83. Chattopadhyay S, Roberts P, Pearce D. The yeast model for Batten disease: a role for Btn2p in the traffcking of the Golgi-associated vesicular targeting protein, Yif1p. Biochem. Biophys. Res. Commun. 302(3), 534-538 (2003). (Pubitemid 36279563)
84. Kama R, Robinson M, Gerst J. Btn2, a Hook1 ortholog and potential Batten disease-related protein, mediates late endosome-Golgi protein sorting in yeast. Mol. Cell. Biol. 27(2), 605-621 (2007). (Pubitemid 46080128)
85. Nair U, Jotwani A, Geng J et al. SNARE proteins are required for macroautophagy. Cell 146(2), 290-302 (2011).
86. Behrends C, Sowa M, Gygi S, Harper J. Network organization of the human autophagy system. Nature 466(7302), 68-76 (2010).
87. Yang Z, Klionsky D. An overview of the molecular mechanism of autophagy. Curr. Top. Microbiol. Immunol. 335, 1-32 (2009).
88. Mukaiyama H, Nakase M, Nakamura T, Kakinuma Y, Takegawa K. Autophagy in the fssion yeast Schizosaccharomyces pombe. FEBS Lett. 584(7), 1327-1334 (2010).
89. Meiringer CT, Auffarth K, Hou H, Ungermann C. Depalmitoylation of Ykt6 prevents its entry into the multivesicular body pathway Traffic 9(9), 1510-1521 (2008).
90. Koike M, Nakanishi H, Saftig P et al. Cathepsin D defciency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci. 20(18), 6898-6906 (2000).